367 related articles for article (PubMed ID: 31337650)
1. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
[TBL] [Abstract][Full Text] [Related]
2. The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells.
Slørdahl TS; Abdollahi P; Vandsemb EN; Rampa C; Misund K; Baranowska KA; Westhrin M; Waage A; Rø TB; Børset M
Oncotarget; 2016 May; 7(19):27295-306. PubMed ID: 27036022
[TBL] [Abstract][Full Text] [Related]
3. B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3.
Lin L; Cao L; Liu Y; Wang K; Zhang X; Qin X; Zhao D; Hao J; Chang Y; Huang X; Liu B; Zhang J; Lu J; Ge Q
Leukemia; 2019 Jun; 33(6):1475-1486. PubMed ID: 30573782
[TBL] [Abstract][Full Text] [Related]
4. Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.
Bhutani M; Pathak AK; Nair AS; Kunnumakkara AB; Guha S; Sethi G; Aggarwal BB
Clin Cancer Res; 2007 May; 13(10):3024-32. PubMed ID: 17505005
[TBL] [Abstract][Full Text] [Related]
5. Functional interplay between NF-κB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma.
Mazzera L; Abeltino M; Lombardi G; Cantoni AM; Ria R; Ricca M; Saltarella I; Naponelli V; Rizzi FMA; Perris R; Corradi A; Vacca A; Bonati A; Lunghi P
Haematologica; 2019 Dec; 104(12):2465-2481. PubMed ID: 30948493
[TBL] [Abstract][Full Text] [Related]
6. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
[TBL] [Abstract][Full Text] [Related]
7. Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases.
Lee JH; Chiang SY; Nam D; Chung WS; Lee J; Na YS; Sethi G; Ahn KS
Cancer Lett; 2014 Apr; 345(1):140-8. PubMed ID: 24333736
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
Bhardwaj A; Sethi G; Vadhan-Raj S; Bueso-Ramos C; Takada Y; Gaur U; Nair AS; Shishodia S; Aggarwal BB
Blood; 2007 Mar; 109(6):2293-302. PubMed ID: 17164350
[TBL] [Abstract][Full Text] [Related]
9. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells.
Pandey MK; Sung B; Aggarwal BB
Int J Cancer; 2010 Jul; 127(2):282-92. PubMed ID: 19937797
[TBL] [Abstract][Full Text] [Related]
10. Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13.
Du T; Song Y; Ray A; Chauhan D; Anderson KC
Leukemia; 2021 Feb; 35(2):550-561. PubMed ID: 32424294
[TBL] [Abstract][Full Text] [Related]
11. URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription.
Fan JL; Zhang J; Dong LW; Fu WJ; Du J; Shi HG; Jiang H; Ye F; Xi H; Zhang CY; Hou J; Wang HY
Cell Death Dis; 2014 Mar; 5(3):e1126. PubMed ID: 24625985
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
13. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
15. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor.
Muto A; Hori M; Sasaki Y; Saitoh A; Yasuda I; Maekawa T; Uchida T; Asakura K; Nakazato T; Kaneda T; Kizaki M; Ikeda Y; Yoshida T
Mol Cancer Ther; 2007 Mar; 6(3):987-94. PubMed ID: 17363492
[TBL] [Abstract][Full Text] [Related]
16. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
[TBL] [Abstract][Full Text] [Related]
17. Src Family Kinases Are Regulated in Multiple Myeloma Cells by Phosphatase of Regenerating Liver-3.
Abdollahi P; Vandsemb EN; Hjort MA; Misund K; Holien T; Sponaas AM; Rø TB; Slørdahl TS; Børset M
Mol Cancer Res; 2017 Jan; 15(1):69-77. PubMed ID: 27698077
[TBL] [Abstract][Full Text] [Related]
18. Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway.
Li F; Rajendran P; Sethi G
Br J Pharmacol; 2010 Oct; 161(3):541-54. PubMed ID: 20880395
[TBL] [Abstract][Full Text] [Related]
19. Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma.
Dimberg LY; Dimberg A; Ivarsson K; Fryknäs M; Rickardson L; Tobin G; Ekman S; Larsson R; Gullberg U; Nilsson K; Öberg F; Wiklund HJ
BMC Cancer; 2012 Jul; 12():318. PubMed ID: 22838736
[TBL] [Abstract][Full Text] [Related]
20. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.
Shi L; Wang S; Zangari M; Xu H; Cao TM; Xu C; Wu Y; Xiao F; Liu Y; Yang Y; Salama M; Li G; Tricot G; Zhan F
Oncotarget; 2010 May; 1(1):22-33. PubMed ID: 20930946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
